Newron Pharmaceuticals S.p.A. (FRA:NP5)

Newron Pharmaceuticals Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 20, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	422	186	95	28	28	35
Market Cap Growth	109.98%	95.60%	239.07%	0.38%	-21.34%	-66.00%
Enterprise Value	432	223	126	44	33	22
Last Close Price	21.55	9.29	5.60	1.47	1.50	1.91
PE Ratio	16.66	11.72	-	-	-	-
PS Ratio	7.05	3.61	10.48	4.59	4.84	6.74
PB Ratio	266.77	127.32	-3.17	-1.99	8.98	2.06
P/TBV Ratio	266.94	127.32	-	-	8.98	2.06
EV/Sales Ratio	7.05	4.34	13.95	7.26	5.77	4.13
EV/EBITDA Ratio	11.93	8.52	-	-	-	-
EV/EBIT Ratio	11.99	8.53	-	-	-	-
Debt / Equity Ratio	33.23	34.62	-1.62	-3.25	13.87	1.53
Debt / EBITDA Ratio	1.49	1.91	-	-	-	-
Net Debt / Equity Ratio	5.92	27.88	-1.20	-1.63	2.73	-0.28
Net Debt / EBITDA Ratio	0.27	1.55	-3.12	-1.72	-0.69	0.27
Net Debt / FCF Ratio	0.38	-2.31	-3.53	-2.06	-0.74	0.31
Asset Turnover	1.39	1.15	0.29	0.14	0.11	0.09
Quick Ratio	1.40	2.42	0.62	5.50	10.58	5.50
Current Ratio	1.51	2.60	0.68	5.65	10.79	5.50
Return on Equity (ROE)	-	-	-	-	-146.43%	-77.71%
Return on Assets (ROA)	50.97%	36.44%	-23.05%	-18.96%	-15.19%	-20.26%
Return on Invested Capital (ROIC)	263.58%	80.74%	-157.51%	-130.08%	-103.26%	-134.50%
Return on Capital Employed (ROCE)	165.20%	64.80%	380.00%	-41.40%	-26.40%	-40.80%
Earnings Yield	6.00%	8.54%	-17.09%	-62.50%	-53.44%	-59.23%
FCF Yield	5.81%	-9.50%	-10.70%	-39.69%	-41.12%	-44.07%
Buyback Yield / Dilution	-16.86%	-15.30%	-	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.